Posts by Matthew R. Smith, MD, PhD
-
Combination of Darolutamide, ADT, and Docetaxel Improves Survival of Patients With Metastatic, Hormone-sensitive Prostate Cancer
Matthew R. Smith, MD, PhD, and colleagues present compelling evidence that survival is significantly better among patients with metastatic, hormone-sensitive prostate cancer who receive darolutamide, androgen-deprivation therapy, and docetaxel than those who receive androgen-deprivation therapy and docetaxel alone.
Biography
Dr. Matthew R. Smith is director of the Genitourinary Oncology Program at Massachusetts General Hospital Cancer Center and an associate professor of Medicine at Harvard Medical School. He graduated summa cum laude from Canisius College with a BA in biochemistry. He received his MD and PhD degrees from Duke University School of Medicine. He trained in Internal Medicine at Brigham and Women's Hospital. He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology.
He is an internationally recognized expert in prostate cancer. He has published extensively on treatment and prevention of bone metastases and prostate cancer survivorship. He has authored more than 150 peer-reviewed articles including manuscripts in New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research. His research is supported by competitive grants and awards from the National Institutes of Health, Lance Armstrong Foundation Research Award, and the Prostate Cancer Foundation.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
